Denintuzumab mafodotin

Drug Profile

Denintuzumab mafodotin

Alternative Names: Anti-CD19-mafodotin; Anti-CD19-mcMMAF; Anti-CD19-vcMMAE; SGN-19A; SGN-CD19A

Latest Information Update: 20 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Seattle Genetics
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Immunomodulators; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diffuse large B cell lymphoma; Follicular lymphoma
  • Phase I Acute lymphoblastic leukaemia; Non-Hodgkin's lymphoma

Most Recent Events

  • 30 May 2017 Seattle Genetics completes a phase I trial in Acute lymphoblastic leukaemia (In adolescents, In adults, In children, In infants, Second-line therapy or greater) and Non-Hodgkin's lymphoma (In adolescents, In adults, In children, In infants, Second-line therapy or greater) in USA (NCT01786096)
  • 16 Feb 2017 Seattle Genetics completes a phase I trial in Acute lymphoblastic leukaemia and Non-Hodgkin's lymphoma (In adolescents, In adults, Second-line therapy or greater) in USA (NCT01786135)
  • 03 Nov 2016 Preclinical data from in non-Hodgkin lymphoma released by Seattle Genetics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top